Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

TitleEfficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Publication TypeJournal Article
Year of Publication2013
AuthorsZhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, Hu Y-M, Wu X, Liu P, Zhu L-Y, Gao F, Jin H, Chen Y-J, Dong Y-Y, Liang Y-C, Shi N-M, Ge H-M, Liu L, Chen S-G, Ai X, Zhang Z-Y, Ji Y-G, Luo F-J, Chen X-Q, Zhang Y, Zhu L-W, Liang Z-L, Shen X-L
JournalLancet
Volume381
Issue9882
Pagination2024-32
Date Published2013 Jun 8
Abstract

A vaccine for enterovirus 71 (EV71) is needed to address the high burden of disease associated with infection. We assessed the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine.

DOI10.1371/journal.pone.0072920
Alternate JournalLancet